<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/30326D2E-953D-4CE9-9350-309A797BD01C"><gtr:id>30326D2E-953D-4CE9-9350-309A797BD01C</gtr:id><gtr:name>HIVACAT Program IrsiCaixa Institute for AIDS Research</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/1ACF2D37-682E-48E9-8C39-AECA9C57614F"><gtr:id>1ACF2D37-682E-48E9-8C39-AECA9C57614F</gtr:id><gtr:name>Immunocore Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Unknown</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/30326D2E-953D-4CE9-9350-309A797BD01C"><gtr:id>30326D2E-953D-4CE9-9350-309A797BD01C</gtr:id><gtr:name>HIVACAT Program IrsiCaixa Institute for AIDS Research</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/1ACF2D37-682E-48E9-8C39-AECA9C57614F"><gtr:id>1ACF2D37-682E-48E9-8C39-AECA9C57614F</gtr:id><gtr:name>Immunocore Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/6D3EDEF4-896A-4E6D-9ACD-25FE64728AA2"><gtr:id>6D3EDEF4-896A-4E6D-9ACD-25FE64728AA2</gtr:id><gtr:firstName>Lucy</gtr:firstName><gtr:surname>Dorrell</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0502048"><gtr:id>4472C1AE-A05F-49C9-AB00-A4E0401F1196</gtr:id><gtr:title>Development of therapeutic vaccination strategies for the treatment of HIV-1 infection</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0502048</gtr:grantReference><gtr:abstractText>The only effective treatment for infection with the human immunodeficiency virus (HIV), the cause of AIDS, is a combination of three anti-HIV drugs taken for life. Less than one in six people living with HIV and in immediate need of treatment are actually receiving it. We are exploring the possibility of using vaccines to boost the body?s immune defences against HIV: the aim is to see whether the immune system can keep the virus at low levels in the bloodstream without continuous drug treatment. We have already seen excellent immune boosting effects with a new HIV vaccine (a modified smallpox vaccine carrying a fragment of HIV, called ?MVA.HIVA?) when it is given to HIV-positive people who are taking anti-HIV drugs. We now need to find out how well vaccinated patients control their virus when their treatment is stopped temporarily. In order to do this we will carry out detailed tests measuring patients? immune responses before, during and after vaccination and then measure HIV levels in the bloodstream while they are off treatment. We will also investigate whether there is greater benefit from using MVA.HIVA together with another vaccine, ?MVA.RENTA?, which carries additional fragments of HIV. If these small studies are successful, we will design a larger study which will aim to test whether vaccination combined with intermittent drug treatment is a realistic alternative to continuous drug treatment. This could have significant benefits for people with HIV as the overall cost and harmful effects of treatment would be reduced.</gtr:abstractText><gtr:technicalSummary>Lifelong treatment with antiretroviral drugs (highly active antiretroviral therapy or HAART) is currently the only means to halt or prevent progression to AIDS but has several limitations, including cost and complexity of treatment regimens, drug toxicity and potential for drug resistance. Exhaustive exploration of drug-sparing treatment strategies which can limit HIV-1 replication is warranted. Enhancement of host cellular immunity by therapeutic vaccination during HAART may potentiate HIV-1 control after drug withdrawal. We have observed significant boosting of virus-specific CD8+ and CD4+ T cell responses in HIV-1-infected patients given a recombinant modified vaccinia virus Ankara (MVA) / HIV-1 gag vaccine (MVA.HIVA) during HAART. Peak responses after vaccination were ten- to 100-fold greater than in HIV-uninfected individuals given the same vaccine. We propose to extend our preliminary findings by conducting a series of experimental studies investigating the potential of MVA.HIVA and another new vaccine, MVA.RENTA (expressing HIV-1 reverse transcriptase, nef, tat and gp41) to stimulate a broad T cell response with the capacity to suppress viral rebound in HIV-1-infected patients undergoing a supervised HAART interruption. These studies will aim to investigate the relationship between breadth, quality and evolution of the immune response, the timing of the treatment interruption and subsequent viral rebound kinetics. These questions have not been adequately addressed by other therapeutic vaccination studies to date, yet are crucial to the design of phase I randomised trials. They may also yield insights into immune correlates of viral containment which could advance prophylactic vaccine development.</gtr:technicalSummary><gtr:fund><gtr:end>2010-08-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>587450</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London (KCL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>CHERUB RIVER</gtr:description><gtr:id>FE4FF4D5-8807-4226-B167-C0A8D79AFFA7</gtr:id><gtr:impact>Application has now been funded by MRC.</gtr:impact><gtr:partnerContribution>Led development of research proposal for submission to MRC DCS scheme
Trial led by Imperial College.</gtr:partnerContribution><gtr:piContribution>Contributed to development of research proposal for submission to MRC DCS scheme.
Contributed to development of clinical trial protocol.
Contributed to immunological data analysis plan.
Am contributing to project management and clinical trial steering.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Oxford Centre for Functional MRI of the Brain FMRIB</gtr:department><gtr:description>Pathophysiology of HIV Cardiovascular Disease</gtr:description><gtr:id>CAF81930-6442-4D1C-BDA4-BBAE6FE4B87A</gtr:id><gtr:impact>Recruitment, MR imaging and blood samples of patients and control subjects for initial study (n = 100) completed. Manuscript published (PMID:23817574) and highlighted in Nature Reviews Cardiology 10, 489 (September 2013). Other manuscripts published since (in publications list).
We have applied for funding to support a 5-year follow-up study.</gtr:impact><gtr:partnerContribution>Provided clinical samples from patients with HIV infection and data which will inform future studies and funding applications.</gtr:partnerContribution><gtr:piContribution>Study design, review of drafts of funding applications and clinical protocol. Recruited patients for the study. Provided training for junior clinical investigator. Assisted with data analysis and manuscript preparation.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>HIVACAT Program IrsiCaixa Institute for AIDS Research</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:description>Irsicaixa-HIVACAT ChAd-MVA.HIVconsv-BCN01 EudraCT: 2011-000846-39</gtr:description><gtr:id>93E036F2-830E-4A08-8CFE-86C1FD8CD260</gtr:id><gtr:impact>Clinical trial application approved and trial is ongoing.</gtr:impact><gtr:partnerContribution>Principal investigator / local investigators for the clinical trial.</gtr:partnerContribution><gtr:piContribution>Drafting of clinical trial protocol and advice on regulatory applications and study design.
Lead applicant on research funding application.</gtr:piContribution><gtr:sector>Multiple</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Immunocore Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Investigation of killing of HIV-infected cells using ImmTAC reagents</gtr:description><gtr:id>7A58EE53-8C6C-4FF3-9DD9-8F0FE4369EA3</gtr:id><gtr:impact>Manuscript published. Further collaborations ongoing.</gtr:impact><gtr:partnerContribution>Provided reagents that have enabled additional experiments for ongoing research project. Provided intellectual input into further work with the ImmTAVs.</gtr:partnerContribution><gtr:piContribution>Collaboration exploits assay which I and my research team have developed. I demonstrated proof-of-concept that the ImmTACs (ImmTAVs) mediate killing of HIV reservoir cells ex vivo from patients on antiretroviral therapy.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>CHERUB RIVER</gtr:description><gtr:id>5C210C4C-BBDA-4CD7-A1AD-B74887894A45</gtr:id><gtr:impact>Application has now been funded by MRC.</gtr:impact><gtr:partnerContribution>Led development of research proposal for submission to MRC DCS scheme
Trial led by Imperial College.</gtr:partnerContribution><gtr:piContribution>Contributed to development of research proposal for submission to MRC DCS scheme.
Contributed to development of clinical trial protocol.
Contributed to immunological data analysis plan.
Am contributing to project management and clinical trial steering.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London (ICL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Imperial College of Science Technology and Medicine (ICSTM)</gtr:department><gtr:description>CHERUB RIVER</gtr:description><gtr:id>7FC8C159-57D8-4E0D-94E5-F856567670E8</gtr:id><gtr:impact>Application has now been funded by MRC.</gtr:impact><gtr:partnerContribution>Led development of research proposal for submission to MRC DCS scheme
Trial led by Imperial College.</gtr:partnerContribution><gtr:piContribution>Contributed to development of research proposal for submission to MRC DCS scheme.
Contributed to development of clinical trial protocol.
Contributed to immunological data analysis plan.
Am contributing to project management and clinical trial steering.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London (UCL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>National Amyloidosis Centre</gtr:department><gtr:description>HIV-CORE 003</gtr:description><gtr:id>B408972A-1DDB-47A4-8073-CC3539578F75</gtr:id><gtr:impact>Clinical trial application approved and trial is ongoing.</gtr:impact><gtr:partnerContribution>Lead investigators of clinical trial combining our vaccines with an agent to improve responses to DNA vaccine through depletion of SAP</gtr:partnerContribution><gtr:piContribution>Design of clinical trial protocol</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Therapeutic HIV vaccines: prior setbacks, current advances, and future prospects.</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A1B423CE-2EB9-4640-A414-05997F82DCEE</gtr:id><gtr:impact>Report published, describing the achievements of the event, in Vaccine 2014 Sep 29;32(43):5540-5. doi: 10.1016/j.vaccine.2014.06.066.


Subsequent publication by NIH program officer, recommending investment in and strategies to advance therapeutic HIV vaccine development.
Shapiro SZ. AIDS Res Hum Retroviruses. 2014 Nov 11. [Epub ahead of print]</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Radio Interview (BBC Radio 4 Today)</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>743D89C1-65AB-4C54-AF6C-A2B423215032</gtr:id><gtr:impact>Interviewed for a radio package - awaiting broadcast

Not yet able to assess</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Weatherall Institute of Molecular Medicine Science Week</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>FFC19D05-7CA4-4C8F-ADC0-DDF7C1FCD6EB</gtr:id><gtr:impact>Open evening attended by ~100 members of public including Year 11-13 students during which I presented an update on my research.

Very positive feedback with requests for more public lectures of a similar kind, including letter from teacher at one of the local schools.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Therapeutic HIV Vaccine Development</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>BC6C3DE8-AA76-4BAA-ADF1-7D0B0843E06F</gtr:id><gtr:impact>Intensive discussion among scientists, patient / community representatives and funders on how to advance the therapeutic vaccine field.

A feedback symposium was convened at AIDS Vaccine 2013 conference, in which I participated as a panel member.
A report on the Workshop is being prepared for publication.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Thames Valley HIV group</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>6FD8B1F6-8CAB-4688-8DA2-A4D5B54442A2</gtr:id><gtr:impact>Gave a research presentation to clinicians, nurses, community workers with interest in HIV.
A colleague gave a separate research presentation for another study for which I am a co-investigator.

Clinicians expressed interest and willingness to expedite recruitment to research studies.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Scientists on the Sofa</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>7755DDC5-CA02-409F-89CC-77658BF505CE</gtr:id><gtr:impact>Panel discussion re vaccine development to members of public at Oxford venue, Science Oxford. Positive feedback received.

None known</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Oxford Biomedical Research Centre open day</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>6CDFECD2-FB46-4858-AC3B-24C1077120FB</gtr:id><gtr:impact>Open day to present research funded wholly / in part by Oxford Biomedical Research Centre to the general public and NHS Trust staff. I presented a poster outlining research which is partly funded by MRC.

None as yet, other than progression of research through joint funding. Proposals to increase impact were discussed afterwards.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>One-to-one meeting with venture capitalist</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E5000AE1-58B4-49D5-A318-9ACC38D48F2A</gtr:id><gtr:impact>Presentation of our HIV vaccine programme, past present and future. Discussion with venture capitalist and Oxford University Head of International Development re potential for future funding.

Raised profile of our research - ongoing discussions with potential funders.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Emergent Biosolutions visit to Oxford University</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>41834FC8-458A-4DD7-B958-7682BE16146A</gtr:id><gtr:impact>Updated industry representatives on HIV vaccine field and novel vaccine approach in development at Oxford University

Industry representatives expressed interest in our work. Potential partners identified.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Training day, Department of Health</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3CD5158B-422D-46DA-B6CB-8D47E1AB1810</gtr:id><gtr:impact>Presented and discussed research experience to assist lay members of ethics committee in decision making regarding assessment of applications for clincal gene therapy trials.

Triage protocol has been developed and implemented by GTAC to enable delegation of assessment of low risk proposals to local research ethics committees.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>7500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>The John Fell Fund</gtr:department><gtr:description>John Fell Fund</gtr:description><gtr:end>2012-12-02</gtr:end><gtr:fundingOrg>University of Oxford</gtr:fundingOrg><gtr:id>0CE392AF-45A9-4767-9792-B11A2795EA5E</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>517780</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Oxford Biomedical Research Centre</gtr:department><gtr:description>NIHR Oxford Biomedical Research Centre</gtr:description><gtr:end>2012-03-02</gtr:end><gtr:fundingOrg>Oxford University Hospitals NHS Trust</gtr:fundingOrg><gtr:id>50AAD465-9F93-44FC-A16F-9FD67AA9DF50</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2007-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Nuffield Department of Medicine</gtr:department><gtr:description>MSc Integrated Immunology, Nuffield Department of Surgery / Medicine</gtr:description><gtr:end>2010-07-02</gtr:end><gtr:fundingOrg>NIHR Oxford Biomedical Research Centre</gtr:fundingOrg><gtr:id>4A189847-09B8-4738-9C1E-252D4092E1AB</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>270994</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>HEFCE Senior Clinical Lectureship</gtr:description><gtr:end>2013-04-02</gtr:end><gtr:fundingOrg>Higher Education Funding Council for England (HEFCE)</gtr:fundingOrg><gtr:id>4EFF1980-410D-45B3-A4A3-A860B7D5177A</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2008-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>651669</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>National Institute for Health Research (NIHR)</gtr:department><gtr:description>Oxford NIHR Biomedical Research Centre</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>University College London Hospitals Charity (UCLH)</gtr:fundingOrg><gtr:id>336185FD-2385-4D91-90AA-A9661359CC29</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2012-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>42300</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC PhD Studentship</gtr:description><gtr:end>2012-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>BD6B7E98-C738-4658-AC5C-911638E82F56</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>4388000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>European Commission FP7 Health 2012 Innovation 1</gtr:description><gtr:end>2017-01-02</gtr:end><gtr:fundingOrg>Community Research and Development Information Service (CORDIS)</gtr:fundingOrg><gtr:fundingRef>305632</gtr:fundingRef><gtr:id>A0BB7C4B-585A-412C-ACDB-A2975DB36B8F</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2013-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>5411</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>British HIV Association Research Award</gtr:description><gtr:end>2010-12-02</gtr:end><gtr:fundingOrg>British HIV Association (BHIVA)</gtr:fundingOrg><gtr:id>DC4D983E-75C2-4015-95EB-78C36CFC7417</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Treatment Action Group / AIDS Vaccine Advocacy Coalition</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>FBD84894-8FDA-4ED5-8A48-4C662B3601DA</gtr:id><gtr:type>Citation in other policy documents</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Gene Therapy Advisory Committee training day</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>BA7AF678-1CD2-457F-AB8A-16C5A2A91966</gtr:id><gtr:impact>Delegation of ethics review of low risk clinical trial applications to NHS ethics committees has helped to accelerate and simplify review process.</gtr:impact><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>MVA.HIVconsv - a vaccine comprising an attenuated poxvirus vector and a novel immunogen based on highly conserved sequences in the HIV-1 proteome. The aim is to induce T cell responses with specificity for diverse viral strains.</gtr:description><gtr:id>BEF89821-7D3D-4047-AF6F-5E2E00BFBDD2</gtr:id><gtr:impact>HIV-CORE 001 - a phase I clinical trial in HIV-seropositive subjects completed in 2013. Safety and immunogenicity data analysis complete. Manuscript has been peer reviewed and revised and final decision is awaited.
A phase I clinical trial in HIV+ subjects initiating antiretroviral therapy during primary HIV infection testing MVA.HIVconsv in combination with chimpanzee adenovirus vectored HIVconsv vaccines in prime-boost regimens is ongoing.</gtr:impact><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Therapeutic immunomodulation in HIV-1 infection</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:ukcrnIsctnId>CSP Ref. 3087,  NCT01024842</gtr:ukcrnIsctnId><gtr:url>http://clinicaltrials.gov/ct2/show/NCT01024842</gtr:url><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>pTHr.HIVconsv, MVA.HIVconsv, ChAdV63.HIVconsv are HIV vaccine candidates that have been tested in 3 different prime-boost combinations in healthy HIV-negative volunteers. Safety evaluations have been completed. Immunogenicity analyses are ongoing. This work is funded by an MRC Experimental Medicine award for which I am a co-applicant.</gtr:description><gtr:id>9D57DD46-066E-490A-9F61-4CA6BAC0D83B</gtr:id><gtr:impact>Immunogenicity data have been published (PMID: 24166483). Other phase I studies are ongoing and funding has been obtained.</gtr:impact><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>HIV-CORE 002 pTHr.HIVconsv, MVA.HIVconsv, ChAdV63.HIVconsv</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:ukcrnIsctnId>NCT01151319</gtr:ukcrnIsctnId><gtr:url>http://clinicaltrials.gov/ct2/show/NCT01151319</gtr:url><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Assay to quantify CD8 cell-mediated suppression of HIV-1 replication in vitro, using flow cytometry to detect cells stained with an HIV-1 p24 antibody.</gtr:description><gtr:id>74141719-C10B-4FA0-A8CF-6251C0C66BC2</gtr:id><gtr:impact>Assay has been evaluated in a chronic HIV infection cohort and subsequently in an acute HIV infection cohort. Assay predicts rate of CD4 cell decline in HIV infection. A manuscript has been published and replication studies in collaboration with internationally renowned research groups have been completed. Further manuscripts have been submitted.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>HIV inhibition assay</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A0AF89DF-5C44-40AF-976A-811E3C5FDA6B"><gtr:id>A0AF89DF-5C44-40AF-976A-811E3C5FDA6B</gtr:id><gtr:title>Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/302ade6eef72f1f78249a8d74c749a76"><gtr:id>302ade6eef72f1f78249a8d74c749a76</gtr:id><gtr:otherNames>Borthwick N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/356A6EC8-D4CB-422C-96A2-3F1CB8D24BB9"><gtr:id>356A6EC8-D4CB-422C-96A2-3F1CB8D24BB9</gtr:id><gtr:title>Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/da746618b1b17a25497b2235af69178a"><gtr:id>da746618b1b17a25497b2235af69178a</gtr:id><gtr:otherNames>Dorrell L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FA944DFC-0074-49C5-A726-F6CD93F11A57"><gtr:id>FA944DFC-0074-49C5-A726-F6CD93F11A57</gtr:id><gtr:title>Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9888e0f37e7d1c89e61cdc32ed5605b0"><gtr:id>9888e0f37e7d1c89e61cdc32ed5605b0</gtr:id><gtr:otherNames>Hanke T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E1A29DDF-5D05-4F5B-AD76-8C77AA64FB33"><gtr:id>E1A29DDF-5D05-4F5B-AD76-8C77AA64FB33</gtr:id><gtr:title>Interleukin-10 responses to therapeutic vaccination during highly active antiretroviral therapy and after analytical therapy interruption.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/976eaddf2bc9b147e2b76a86d7e294d5"><gtr:id>976eaddf2bc9b147e2b76a86d7e294d5</gtr:id><gtr:otherNames>Yang H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/762A4E45-5EA0-4FD5-A480-96FBE6865BD5"><gtr:id>762A4E45-5EA0-4FD5-A480-96FBE6865BD5</gtr:id><gtr:title>Impaired IFN-gamma-secreting capacity in mycobacterial antigen-specific CD4 T cells during chronic HIV-1 infection despite long-term HAART.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9c2945ace3efa22614ab021aa4d79d47"><gtr:id>9c2945ace3efa22614ab021aa4d79d47</gtr:id><gtr:otherNames>Sutherland R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/49CAC888-3B50-4308-BAF8-6F776D9F4AF2"><gtr:id>49CAC888-3B50-4308-BAF8-6F776D9F4AF2</gtr:id><gtr:title>Improved quantification of HIV-1-infected CD4+ T cells using an optimised method of intracellular HIV-1 gag p24 antigen detection.</gtr:title><gtr:parentPublicationTitle>Journal of immunological methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/976eaddf2bc9b147e2b76a86d7e294d5"><gtr:id>976eaddf2bc9b147e2b76a86d7e294d5</gtr:id><gtr:otherNames>Yang H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1759</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7F300C77-A875-4C43-B9B0-25B637105CAB"><gtr:id>7F300C77-A875-4C43-B9B0-25B637105CAB</gtr:id><gtr:title>Comprehensive analysis of HIV Gag-specific IFN-gamma response in HIV-1- and HIV-2-infected asymptomatic patients from a clinical cohort in The Gambia.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0176ac52f7a3858de3221c9d5a7dfd0a"><gtr:id>0176ac52f7a3858de3221c9d5a7dfd0a</gtr:id><gtr:otherNames>Ondondo BO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/56B80864-47E6-4C5D-BC02-EBA3636BC51B"><gtr:id>56B80864-47E6-4C5D-BC02-EBA3636BC51B</gtr:id><gtr:title>Direct quantification of cell-associated HIV DNA in isolated rectal and blood memory CD4 T cells revealed their similar and low infection levels in long-term treated HIV-infected patients.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/424009bd03246354bfa72c1cd6943bb9"><gtr:id>424009bd03246354bfa72c1cd6943bb9</gtr:id><gtr:otherNames>Descours B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/77649E82-B243-4783-AC2E-90BD98ED06EA"><gtr:id>77649E82-B243-4783-AC2E-90BD98ED06EA</gtr:id><gtr:title>Design and pre-clinical evaluation of a universal HIV-1 vaccine.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/94b2f585dc4d4206ae8515f3b522e7d5"><gtr:id>94b2f585dc4d4206ae8515f3b522e7d5</gtr:id><gtr:otherNames>L?tourneau S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0C783A2D-AC82-478F-8E31-C3627C1BC3D8"><gtr:id>0C783A2D-AC82-478F-8E31-C3627C1BC3D8</gtr:id><gtr:title>A step ahead on the HIV collaboratory.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b583d4e22846ff5412f9612b35343b60"><gtr:id>b583d4e22846ff5412f9612b35343b60</gtr:id><gtr:otherNames>Murphy RL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/456E8EAA-98E0-41FB-95B2-EE669FF3F06D"><gtr:id>456E8EAA-98E0-41FB-95B2-EE669FF3F06D</gtr:id><gtr:title>Broad TCR usage in functional HIV-1-specific CD8+ T cell expansions driven by vaccination during highly active antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/976eaddf2bc9b147e2b76a86d7e294d5"><gtr:id>976eaddf2bc9b147e2b76a86d7e294d5</gtr:id><gtr:otherNames>Yang H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A06E89DC-B7C7-4AAF-9B16-CA24D0A95F02"><gtr:id>A06E89DC-B7C7-4AAF-9B16-CA24D0A95F02</gtr:id><gtr:title>Lessons from IAVI-006, a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b709ad3b8e7698295cad3772f08cf235"><gtr:id>b709ad3b8e7698295cad3772f08cf235</gtr:id><gtr:otherNames>Guimar?es-Walker A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5AFF0AA5-624E-4F2B-87CF-6DF20FD3E8B4"><gtr:id>5AFF0AA5-624E-4F2B-87CF-6DF20FD3E8B4</gtr:id><gtr:title>Development of prophylactic vaccines against HIV-1.</gtr:title><gtr:parentPublicationTitle>Retrovirology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/07383f1be695ee1c3e051f35970d41e2"><gtr:id>07383f1be695ee1c3e051f35970d41e2</gtr:id><gtr:otherNames>Schiffner T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1742-4690</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D798D0F6-4973-4C83-8E82-4684B071ED00"><gtr:id>D798D0F6-4973-4C83-8E82-4684B071ED00</gtr:id><gtr:title>Immunisation with recombinant modified vaccinia virus Ankara expressing HIV-1 gag in HIV-1-infected subjects stimulates broad functional CD4+ T cell responses.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0176ac52f7a3858de3221c9d5a7dfd0a"><gtr:id>0176ac52f7a3858de3221c9d5a7dfd0a</gtr:id><gtr:otherNames>Ondondo BO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C0444298-E596-41F9-BD9C-F9D676D7D6CB"><gtr:id>C0444298-E596-41F9-BD9C-F9D676D7D6CB</gtr:id><gtr:title>Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a8af3eae12e9c3485ab2e2ff801c5b9f"><gtr:id>a8af3eae12e9c3485ab2e2ff801c5b9f</gtr:id><gtr:otherNames>Cebere I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/81F76646-21BA-489C-A93D-FDDCDC547A58"><gtr:id>81F76646-21BA-489C-A93D-FDDCDC547A58</gtr:id><gtr:title>Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0e7b5bfbb7d685aef71a3b09b947ac84"><gtr:id>0e7b5bfbb7d685aef71a3b09b947ac84</gtr:id><gtr:otherNames>Howles S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/981D3750-A017-4D51-BAAE-BC22BD39FF67"><gtr:id>981D3750-A017-4D51-BAAE-BC22BD39FF67</gtr:id><gtr:title>Linking genotype to phenotype on beads: high throughput selection of peptides with biological function.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/63dd7815b106ce172e0bae9d5d1fe643"><gtr:id>63dd7815b106ce172e0bae9d5d1fe643</gtr:id><gtr:otherNames>Huang LC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F2E90ECD-D967-49F3-8FFF-01F7F3CE74D4"><gtr:id>F2E90ECD-D967-49F3-8FFF-01F7F3CE74D4</gtr:id><gtr:title>Therapeutic immunization for the control of HIV-1: where are we now?</gtr:title><gtr:parentPublicationTitle>International journal of STD &amp; AIDS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/da746618b1b17a25497b2235af69178a"><gtr:id>da746618b1b17a25497b2235af69178a</gtr:id><gtr:otherNames>Dorrell L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0956-4624</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/003EB0B7-D38B-492A-982E-8D49484B0476"><gtr:id>003EB0B7-D38B-492A-982E-8D49484B0476</gtr:id><gtr:title>Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/60dd7c7f3e69e5d82c331af4071a55b4"><gtr:id>60dd7c7f3e69e5d82c331af4071a55b4</gtr:id><gtr:otherNames>Papagno L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B160E769-1752-4958-80C8-6D06B9D49D41"><gtr:id>B160E769-1752-4958-80C8-6D06B9D49D41</gtr:id><gtr:title>Antiviral inhibitory capacity of CD8+ T cells predicts the rate of CD4+ T-cell decline in HIV-1 infection.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/976eaddf2bc9b147e2b76a86d7e294d5"><gtr:id>976eaddf2bc9b147e2b76a86d7e294d5</gtr:id><gtr:otherNames>Yang H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B658F12B-721A-42B2-BA26-CB730CA36E0F"><gtr:id>B658F12B-721A-42B2-BA26-CB730CA36E0F</gtr:id><gtr:title>The immune response to HIV</gtr:title><gtr:parentPublicationTitle>Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/fb31ea3365a8586f91a885710976be89"><gtr:id>fb31ea3365a8586f91a885710976be89</gtr:id><gtr:otherNames>McMichael A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7E84ABCE-A526-45FE-AE25-5AFE20765641"><gtr:id>7E84ABCE-A526-45FE-AE25-5AFE20765641</gtr:id><gtr:title>Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/943afd66240b87a716970ccd9ece4a71"><gtr:id>943afd66240b87a716970ccd9ece4a71</gtr:id><gtr:otherNames>Goonetilleke N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A0C6C9F6-E8C6-48CE-8273-D1A2948B4E9A"><gtr:id>A0C6C9F6-E8C6-48CE-8273-D1A2948B4E9A</gtr:id><gtr:title>Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/da746618b1b17a25497b2235af69178a"><gtr:id>da746618b1b17a25497b2235af69178a</gtr:id><gtr:otherNames>Dorrell L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0502048</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>